trial

24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia

NCTId NCT00752427
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 86 (actual)
Sponsored by Johnson & Johnson
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
86 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2004-06
Primary completion
—
Eligibility
ALL · 65 Years

Interventions & indications

Drugs
Paliperidone

Sponsors

Johnson & JohnsonLead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
86
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
lead_sponsor
Johnson & Johnson
company
indication
Schizophrenia
indication
Schizophrenia
indication